Link | Meyd-773

The ship’s interior was divided into three primary zones:

MEYD‑773 displayed >250‑fold selectivity for class I PI3K over other kinases, with negligible activity against mTOR, DNA‑PK, and CDK families. In vitro, MEYD‑773 reduced p‑AKT (Ser473) and p‑S6 (Ser235/236) levels with EC₅₀ ≈ 30 nM, induced G₁ arrest, and triggered caspase‑3/7‑mediated apoptosis selectively in PI3K‑mutant TNBC cells (IC₅₀ = 0.08‑0.15 µM). PK studies revealed oral bioavailability of 68 %, a half‑life of 7.2 h, and plasma exposure exceeding the in‑vitro EC₅₀ for >12 h at 20 mg kg⁻¹. In orthotopic MDA‑MB‑231 models, daily oral dosing (20 mg kg⁻¹) produced a tumor growth inhibition (TGI) of 82 % (p < 0.001) without weight loss or histopathologic toxicity. In three independent TNBC PDX models (BRCA1‑mutated, PTEN‑null, and wild‑type PI3K), MEYD‑773 achieved TGIs of 71‑89 % and prolonged median survival by 3‑4‑fold compared with vehicle. Combination with standard‑of‑care paclitaxel showed synergistic tumor regression (Combination Index = 0.46). MEYD-773

Data are presented as mean ± SD. Comparisons between groups used one‑way ANOVA with Tukey’s post‑hoc test or log‑rank test for survival. Synergy was evaluated using the Chou–Talalay method (Combination Index < 1 indicates synergism). P‑values < 0.05 were considered statistically significant. The ship’s interior was divided into three primary

: If you've used similar products, a comparison can be helpful. How does "MEYD-773" stack up against others in its category? In orthotopic MDA‑MB‑231 models, daily oral dosing (20

The adult entertainment industry is a complex and multifaceted market that has experienced significant growth and changes in recent years. Some key trends and insights include: